Description: Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 while maintaining the stock’s Outperform rating. The firm cited a number of factors for the adjustment, including a longer exclusivity period for Biktarvy, with […]

Description: Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for HIV prevention to Eswatini and Zambia, marking a significant step in global access initiatives for this therapy. This move highlights Gilead’s ability to rapidly bring innovative HIV prevention to regions with high disease burden, fostering global health partnerships and expanding its reach in emerging markets. We'll now explore how Gilead's expanded...

Description: Ever wondered if Gilead Sciences might be trading for less than it's worth? Let’s dig into its recent moves to see if there's a value opportunity hiding in plain sight. Gilead Sciences' stock has been on the rise, climbing 6.2% over the past month and surging 37.0% year-to-date, for a strong 40.0% jump over the last year. Healthcare headlines have been buzzing, with recent positive developments around Gilead’s pipeline treatments and strategic partnerships attracting fresh attention from...

Description: GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.

Description: KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.

Description: Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.

Description: Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.

Description: The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”

Description: FOSTER CITY, Calif., November 24, 2025--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina,

Description: The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.

Description: Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

Description: Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease.

Description: Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining about 4%. With steady annual revenue and net income growth, there is renewed interest in how the company is positioned within the sector. See our latest analysis for Gilead Sciences. Gilead Sciences has enjoyed a wave of positive momentum lately, with its latest share price of $128.07 reflecting strong interest. The company’s share price return year-to-date stands at...

Description: FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.

Description: Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco

Description: The global portal hypertension drugs market is thriving due to rising liver disease rates, particularly cirrhosis and hepatitis, and an aging global population, leading to heightened demand for effective therapies. Key players like Gilead Sciences and Novartis are driving market growth through innovation and strategic partnerships. Despite challenges such as high treatment costs and limited access, ongoing R&D aims to introduce affordable solutions. As awareness of liver health expands, technolo

Description: FOSTER CITY, Calif. & MBABANE, Eswatini, November 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livi

Description: Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 12, Scotiabank an⁠aly​st Louise Chen began coverage on ten large-cap biopharma companies an⁠d sh​ared‍ an “‍o‌ut-of-c⁠onsensus” positive view o‌n the‍ sector, according to a report by The Fly. She pointed out that years of underperfor‍manc‌e in […]

Description: Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.

Description: Gilead Sciences recently announced that its Phase 3 ARTISTRY-1 trial met the primary endpoint for a novel single-tablet HIV regimen combining bictegravir and lenacapavir, confirming non-inferiority versus multi-tablet therapy and reporting a favorable safety profile. This development highlights Gilead’s continued progress in simplifying treatment for people living with HIV and advancing next-generation regimens that address patient needs for convenience and tolerability. We’ll examine how...

Description: Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

Description: Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More

Description: FOSTER CITY, Calif., November 13, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file t

Description: Curious whether Gilead Sciences is a hidden gem or if the current stock price already reflects all its upside? Let’s break down the numbers and see if there's value yet to be uncovered. After a strong year with a 37.2% gain and an impressive 34.3% jump year to date, the market’s perception of Gilead’s risk and growth potential appears to be evolving. Recent headlines highlight the company’s steady stream of new treatment approvals and strategic partnerships, both of which have bolstered...

Description: Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on devel

Description: Compugen Ltd (CGEN) showcases promising drug discovery initiatives and strategic partnerships, despite facing revenue declines and trial delays.

Description: Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Art

Description: Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the third quarter of 2025 and provided a corporate update.

Description: LOS ANGELES, November 10, 2025--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that will circle the venue (Convene 22 Bishopsgate) on Nov. 11-12 to spotlight Gilead Sciences’ greed and refusal to make its breakthrough HIV prevention drug lenacapavir truly affordable and accessible.

Description: Recent analyst updates have led to a slight increase in Gilead Sciences’ fair value price target, moving from $127.23 to $129.51. This change is supported by renewed confidence in the company’s performance and potential, along with a minor uptick in perceived investment risk. Stay tuned to see how you can keep up with evolving perspectives in this dynamic narrative. Stay updated as the Fair Value for Gilead Sciences shifts by adding it to your watchlist or portfolio. Alternatively, explore...

Description: Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%

Description: Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se

Description: Gilead Sciences (GILD) said Friday that new long-term data on its drug Livdelzi showed consistent ef

Description: FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria.

Description: FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes in patients switching from obeticholic acid and positive impact on liver stiffness over 3 years. These findings were presented at The Liver Meeting® hosted by the American Association for the

Description: Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with

Description: Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader commercial headwinds. Management credited the quarter’s performance to robust demand for Biktarvy and Descovy, as well as the successful launch of Yeztugo for HIV prevention and Livdelzi for liver disease. CEO Daniel O’Day specifically highlighted the company’s “disciplined operating expense manage

Description: Gilead Sciences (GILD) released its third quarter earnings, showing a big jump in net income and earnings per share from last year. The company also raised its full-year profit outlook, which signals momentum. See our latest analysis for Gilead Sciences. Gilead Sciences has been on investors’ radar thanks to its raised earnings guidance and positive clinical updates, which have helped drive solid momentum. The stock boasts a year-to-date share price return of 33% and a stellar one-year total...

Description: Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: FOSTER CITY, Calif., November 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

Description: Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.

Description: FOSTER CITY, Calif., November 03, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9). These data showcase Kite’s continued progress in transforming blood cancer care and expanding the reach and impact of CAR T-cell therapy.

Description: Gilead Sciences (GILD) delivered a net profit margin of 27.9%, a sharp turnaround from just 0.4% a year ago, with earnings growth skyrocketing 6336.5% year over year. Looking ahead, management expects earnings to rise by 9.08% annually and revenue to grow at 4.5% per year, pointing to continued but more tempered expansion. Investors are weighing these strong headline results against prospects for steady future growth and value, especially with the company’s share price sitting below one major...

Description: In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o

Description: Gilead stock reversed higher on smaller losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.

Description: Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.

Description: FOSTER CITY, Calif., October 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceuti

Description: NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Pu

Description: Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

Description: Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy sales.

Description: Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention drug, Yeztugo.

Description: Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Gilead Sciences reported third-quarter results that surpassed Wall Street expectations late Thursday, amid a close focus on the launch of the company’s promising new HIV medicine. Gilead shares are up 30% this year, largely on enthusiasm for Yeztugo, a twice-yearly HIV prevention shot that the FDA approved in June. Gilead said Thursday that sales of Yeztugo had been $39 million in the third quarter.

Description: Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.

Description: GILD) on Thursday reported third-quarter earnings of $3.05 billion. On a per-share basis, the Foster City, California-based company said it had profit of $2.43. Earnings, adjusted for one-time gains and costs, came to $2.47 per share.

Description: FOSTER CITY, Calif., October 30, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations.

Description: New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busin

Description: In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and presented new positive clinical data across its liver disease and oncology pipeline at major global conferences. This wave of regulatory and clinical milestones underscores Gilead's momentum in diversifying beyond its HIV franchise with late-stage therapies addressing major unmet needs. We'll examine how Health Canada’s approval for LYVDELZI and strong...

Description: WASHINGTON, October 29, 2025--Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes

Description: Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.

Description: Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect.

Description: AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Description: The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Description: If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, but rather with a sense of real momentum. Maybe you are holding the stock yourself and considering whether to double down, or perhaps you are just circling, wondering if now is finally the time to buy in. Let’s dig in together and see what might be going on beneath the surface. Over the last week, Gilead’s shares climbed 2.7%, which isn’t life-changing in itself, but...

Description: Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: FOSTER CITY, Calif., October 23, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and viral hepatitis will include late-breaking data and three oral presentations.

Description: Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior day's close.

Description: Gilead Sciences will release its third-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Description: Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA alone, or as monotherapy in patients unable to tolerate UDCA. This market authorization has been issued with conditions pending the results of trials to verify its clinical benefit.

Description: WASHINGTON, October 21, 2025--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP

Description: FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communit

Description: FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented to

Description: Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS Conference and the European Society for Medical Oncology. Updates include HIV treatment advances and important data from cancer trials. See our latest analysis for Gilead Sciences. After unveiling positive data at major scientific conferences, Gilead Sciences is enjoying a notable run, with its share price climbing nearly 34% year-to-date and delivering an impressive 1-year...